{"entity":{"id":"nct04725474","kind":"trial","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","aka":[],"tldr":"A phase 1/2 trial of Visugromab and Nivolumab in advanced solid tumours, run by CatalYm GmbH, active and no longer recruiting.","summary":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) is a phase 1/2 interventional study registered as NCT04725474 by CatalYm GmbH, with 199 participants enrolled, started 2020-12-09 and due to reach its primary completion in 2028-04-30. Interventions recorded: visugromab (CTL-002) and nivolumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04725474","url":"https://clinicaltrials.gov/study/NCT04725474"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["visugromab","nivolumab"],"companies":["catalym"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04725474","phase":"1/2","setting":"A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The \"GDFATHER\"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).","sponsor":"CatalYm GmbH","enrolled":199,"outcomes":[]},"route":"/trials/nct04725474/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"visugromab","kind":"drug","name":"Visugromab","route":"/drugs/visugromab/"}],"company":[{"id":"catalym","kind":"company","name":"CatalYm","route":"/companies/catalym/"}]}}